AAM Statement — Restricting Patent Settlements Hurts Patients
Banning Patent Litigation Settlements Will Keep Biosimilars and Generic Drugs Off the Market No Patient Benefit - Only Helps Big Pharma Companies Abusing the Patent System
MEDIA ADVISORY
Op-Ed from STAT — Grassley, Leahy: It's Time to Empower Generic Drug Makers to Bring Down Prices
By Patrick Leahy and Chuck Grassley
March 16, 2018
The CREATES Act - A Conservative Market-based Solution to Lower Drug Prices
2017 AAM Annual Report
2017 Was Epic
The landscape around us looks much different today than it did just one year ago. As our industry changes within the evolving pharmaceutical ecosystem, we must speak with one voice to drive home the message that a robust generic drug and biosimilars marketplace is necessary to sustain affordable health care.
AAM White Paper: Ensuring the Future of Accessible Medicines in the U.S.
Patient health and well-being depends on the uninterrupted availability of lower-cost generic and biosimilar medicines. Moreover, as patients live longer the importance of a robust and sustainable generic and biosimilar medicines industry becomes only that much more important. Policymakers must act quickly to ensure continued saving and market-based competition, as well as prevent shortages, for future availability of affordable medicines. This requires:
Help Pass the CREATES Act
Anticompetitive practices prevent patients from accessing the generic and biosimilar medicines they need.
Congress is currently considering a fix, the Creating and Restoring Equal Access to Equivalent Samples (“CREATES”) Act. Encourage your members of Congress to pass this important bill that will bring down costs and increase patient access to life-saving medicines.
Watch this CBS News story that explains the challenge facing so many Americans, like cancer patient, Pam Holt. You, like Pam, can make a difference.
Dear Mr. President
“To speed access to breakthrough cures and affordable generic drugs, last year the FDA approved more new and generic drugs and medical devices than ever before in our history.”
In his first State of the Union, President Donald Trump stressed the importance of approving safe and affordable generic drugs.
#EndtheShenanigans, Says Gottlieb
Dr. Scott Gottlieb, Commissioner of Food and Drugs, has adopted a bold stance on behalf of patient access to affordable medicines. In particular, he is targeting REMS abuse — by which some bad actors prevent generic firms from purchasing the doses of a branded drug that they need to run their studies — for the way it undermines the sustainable competition necessary for FDA-approved generic drugs and biosimilars to reach patients.
AAM Tells Senate: Generics Are Solution to High Drug Prices
On October 17, 2017, the Senate Health, Education, Labor and Pensions Committee, under the leadership of Senators Lamar Alexander (R-TN) and Patty Murray (D-WA), convened a hearing to explore why drug prices are so high. The committee asked trade associations representing different parts of the prescription drug supply chain – manufacturers, wholesalers, pharmacy benefits managers and pharmacists – to help it understand what can be done to provide some relief for the millions of Americans burdened by skyrocketing prescription drug costs.
Support the CREATES Act and Help Patients Win
“The objective is to win: fairly, squarely, decently, win by the rules, but still win.” – Vince Lombardi
When it comes to prescription medicines, patients win when companies innovate new cures and treatments. Patients also win when more affordable generic versions of those medicines enter the market. Unfortunately, some brand manufacturers aren’t playing by the rules.